A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

Exclusion Criteria

• •Individuals who:
• •1. For the unvaccinated groups only, previously received any investigational or authorized MERS-CoV, SARS-CoV, and SARS-CoV-2 vaccines (including ARCT-021)
• •2. For the previously vaccinated groups only, previously received BNT162b2 but have not received 2 doses within at least 5 months prior to study enrollment
• •3. Are planning to receive other COVID-19 vaccines during the study period
• •4. Recently received other vaccines
• •5. Have a fever or are feeling sick close to the time of the first study vaccination
• •6. Have a known history of COVID-19 disease or asymptomatic SARS-CoV-2 infection
• •7. Are pregnant or breastfeeding
• •8. Have had a severe reaction to previous vaccines
• •9. Have a severe or uncontrolled disease(s) that may interfere with the interpretation of the study
• •10. Have some respiratory diseases
• •11. Have some significant heart diseases
• •12. Have some neurological conditions
• •13. Have sickle cell disease or some other blood disorders
• •14. Have had a major surgery within the past 6 months
• •15. Have a history of chronic liver disease
• •16. Have a history of autoimmune disease or immunodeficiency
• •17. Have received allergy injections, interferon, immunomodulators, cytotoxic drugs or other similar toxic drugs.
• •18. Have received blood products
• •19. Have a positive test for hepatitis B or C or human immunodeficiency virus
• •20. Have uncontrolled hypertension
• •21. Have had cancer except for cancers that were treated and that have low risk of returning
• •22. Are obese
• •23. Are Investigator site staff members, employees of Arcturus or the contract research organization (CRO) directly involved in the conduct of the study, or site staff members otherwise supervised by the Investigator or immediate family members of any of the previously mentioned individuals